Natural Killer Cell Lymphomas – Pipeline Review, H2 2012

  • July 2012
  • -
  • Global Markets Direct
  • -
  • 74 pages

Natural Killer Cell Lymphomas – Pipeline Review, H2 2012



Summary



Global Markets Direct’s, 'Natural Killer Cell Lymphomas - Pipeline Review, H2 2012', provides an overview of the Natural Killer Cell Lymphomas therapeutic pipeline. This report provides information on the therapeutic development for Natural Killer Cell Lymphomas, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Natural Killer Cell Lymphomas. 'Natural Killer Cell Lymphomas - Pipeline Review, H2 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.



Scope


- A snapshot of the global therapeutic scenario for Natural Killer Cell Lymphomas.
- A review of the Natural Killer Cell Lymphomas products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Natural Killer Cell Lymphomas pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.



Reasons to buy


- Identify and understand important and diverse types of therapeutics under development for Natural Killer Cell Lymphomas.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Natural Killer Cell Lymphomas pipeline depth and focus of Natural Killer Cell Lymphomas therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table Of Contents

Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Natural Killer Cell Lymphomas Overview 8
Therapeutics Development 9
An Overview of Pipeline Products for Natural Killer Cell Lymphomas 9
Natural Killer Cell Lymphomas Therapeutics under Development by Companies 11
Natural Killer Cell Lymphomas Therapeutics under Investigation by Universities/Institutes 12
Late Stage Products 14
Comparative Analysis 14
Mid Clinical Stage Products 15
Comparative Analysis 15
Early Clinical Stage Products 16
Comparative Analysis 16
Natural Killer Cell Lymphomas Therapeutics - Products under Development by Companies 17
Natural Killer Cell Lymphomas Therapeutics - Products under Investigation by Universities/Institutes 18
Companies Involved in Natural Killer Cell Lymphomas Therapeutics Development 20
Kyowa Hakko Kirin Co., Ltd. 20
Seattle Genetics, Inc. 21
Natural Killer Cell Lymphomas - Therapeutics Assessment 22
Assessment by Monotherapy Products 22
Assessment by Combination Products 23
Assessment by Route of Administration 24
Assessment by Molecule Type 26
Drug Profiles 28
Poteligeo - Drug Profile 28
Product Description 28
Mechanism of Action 28
RandD Progress 28
Clofarabine - Drug Profile 30
Product Description 30
Mechanism of Action 30
RandD Progress 30
C-CHOP - Drug Profile 31
Product Description 31
Mechanism of Action 31
RandD Progress 31
Vorinostat + Azacitidine - Drug Profile 33
Product Description 33
Mechanism of Action 33
RandD Progress 33
Dexamethasone + Ifosfamide + Cisplatin + Etoposide - Drug Profile 34
Product Description 34
Mechanism of Action 34
RandD Progress 34
Rituximab + Siplizumab + Cyclophosphamide + Doxorubicin + Etoposide + Prednisone + Vincristine + Filgrastim - Drug Profile 35
Product Description 35
Mechanism of Action 35
RandD Progress 36
RAD001 + Revlimid - Drug Profile 37
Product Description 37
Mechanism of Action 37
RandD Progress 37
L-Asparaginase + Methotrexate + Dexamethasone - Drug Profile 38
Product Description 38
Mechanism of Action 38
RandD Progress 38
Treanda + Carboplatin + Rituximab + Etoposide - Drug Profile 40
Product Description 40
Mechanism of Action 40
RandD Progress 41
Nelfinavir + Bortezomib - Drug Profile 42
Product Description 42
Mechanism of Action 42
RandD Progress 42
Umbilical Cord Blood Transplantation - Drug Profile 43
Product Description 43
Mechanism of Action 43
RandD Progress 43
BuEAM + Autologous Stem Cell Transplantation - Drug Profile 45
Product Description 45
Mechanism of Action 45
RandD Progress 46
Lenalidomide + Rituximab + Carmustine + Etoposide + Cytarabine + Melphalan + Autologous Hematopoietic Stem Cell Transplant - Drug Profile 47
Product Description 47
Mechanism of Action 48
RandD Progress 48
Carmustine + Etoposide + Cytarabine + Fludarabine Phosphate + Cyclophosphamide + Tacrolimus + Mycophenolate Mofetil + Melphalan + Filgrastim + Stem Cell Transplantation + Radiation Therapy - Drug Profile 50
Product Description 50
Mechanism of Action 51
RandD Progress 52
CHOP + Campath-1H - Drug Profile 53
Product Description 53
Mechanism of Action 53
RandD Progress 53
Fludarabine Phosphate + Total-Body Irradiation + Peripheral Blood Stem Cell Transplantation + Cyclosporine + Mycophenolate Mofetil - Drug Profile 54
Product Description 54
Mechanism of Action 54
RandD Progress 55
Campath-1H + Cyclophosphamide + Doxorubicin Hydrochloride + Etoposide + Prednisone + Vincristine Sulfate - Drug Profile 56
Product Description 56
Mechanism of Action 56
RandD Progress 57
L-Asparaginase - Drug Profile 58
Product Description 58
Mechanism of Action 58
RandD Progress 58
SGN-35 + Cyclophosphamide + Prednisone + Doxorubicin + Vincristine - Drug Profile 59
Product Description 59
Mechanism of Action 59
RandD Progress 60
Cyclophosphamide + Adriamycin + Vincristine + Prednisone + Radiation Therapy - Drug Profile 61
Product Description 61
Mechanism of Action 61
RandD Progress 61
Carfilzomib - Drug Profile 63
Product Description 63
Mechanism of Action 63
RandD Progress 63
Cisplatin + L-Asparaginase + Methotrexate + Ifosfamide + Dexamethasone + Etoposide + Radiation Therapy - Drug Profile 64
Product Description 64
Mechanism of Action 64
RandD Progress 65
SGN-35 + Cyclophosphamide + Prednisone + Doxorubicin - Drug Profile 66
Product Description 66
Mechanism of Action 66
RandD Progress 67
LBH589 - Drug Profile 68
Product Description 68
Mechanism of Action 68
RandD Progress 68
Natural Killer Cell Lymphomas Therapeutics - Drug Profile Updates 69
Natural Killer Cell Lymphomas Therapeutics - Discontinued Products 71
Natural Killer Cell Lymphomas Therapeutics - Dormant Products 72
Appendix 73
Methodology 73
Coverage 73
Secondary Research 73
Primary Research 73
Expert Panel Validation 73
Contact Us 74
Disclaimer 74

List of Tables

Number of Products Under Development for Natural Killer Cell Lymphomas, H2 2012 9
Products under Development for Natural Killer Cell Lymphomas - Comparative Analysis, H2 2012 10
Number of Products under Development by Companies, H2 2012 11
Number of Products under Investigation by Universities/Institutes, H2 2012 13
Comparative Analysis by Late Stage Development, H2 2012 14
Comparative Analysis by Mid Clinical Stage Development, H2 2012 15
Comparative Analysis by Early Clinical Stage Development, H2 2012 16
Products under Development by Companies, H2 2012 17
Products under Investigation by Universities/Institutes, H2 2012 18
Products under Investigation by Universities/Institutes, H2 2012 (Contd..1) 19
Kyowa Hakko Kirin Co., Ltd., H2 2012 20
Seattle Genetics, Inc., H2 2012 21
Assessment by Monotherapy Products, H2 2012 22
Assessment by Combination Products, H2 2012 23
Assessment by Stage and Route of Administration, H2 2012 25
Assessment by Stage and Molecule Type, H2 2012 27
Natural Killer Cell Lymphomas Therapeutics - Drug Profile Updates 69
Natural Killer Cell Lymphomas Therapeutics - Discontinued Products 71
Natural Killer Cell Lymphomas Therapeutics - Dormant Products 72

List of Figures

Number of Products under Development for Natural Killer Cell Lymphomas, H2 2012 9
Products under Development for Natural Killer Cell Lymphomas - Comparative Analysis, H2 2012 10
Products under Development by Companies, H2 2012 11
Products under Investigation by Universities/Institutes, H2 2012 12
Late Stage Products, H2 2012 14
Mid Clinical Stage Products, H2 2012 15
Early Clinical Stage Products, H2 2012 16
Assessment by Monotherapy Products, H2 2012 22
Assessment by Combination Products, H2 2012 23
Assessment by Route of Administration, H2 2012 24
Assessment by Stage and Route of Administration, H2 2012 25
Assessment by Molecule Type, H2 2012 26
Assessment by Stage and Molecule Type, H2 2012 27

View This Report »

Find all the market research you need - instantly, in one place.

+1.2 Million Research Documents & Statistics +200,000 Trusted Public Sources 350 Industries With Global Coverage

24/7 Customer Support

Talk to Clare

+1 339 368 6001

Purchase Reports From Reputable Market Research Publishers

Degenerative Disc Disease - Pipeline Review, H1 2014

Degenerative Disc Disease - Pipeline Review, H1 2014

  • $ 2 000
  • Company report
  • June 2014
  • by Global Markets Direct

Degenerative Disc Disease - Pipeline Review, H1 2014 Summary Global Markets Direct's, ‘Degenerative Disc Disease - Pipeline Review, H1 2014', provides an overview of the Degenerative Disc Disease's therapeutic ...

World Therapy: Critical Limb Ischemia – Pipeline Review, H1 2012

World Therapy: Critical Limb Ischemia – Pipeline Review, H1 2012

  • $ 2 000
  • Company report
  • June 2014
  • by Global Markets Direct

This report provides data on the therapeutic development for Critical Limb Ischemia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players ...

International Stem Cell Corporation - Product Pipeline Review - 2014

International Stem Cell Corporation - Product Pipeline Review - 2014

  • $ 1 500
  • Company report
  • June 2014
  • by Global Markets Direct

International Stem Cell Corporation - Product Pipeline Review - 2014 Summary Global Markets Direct's, ‘International Stem Cell Corporation - Product Pipeline Review - 2014', provides an overview of the ...


ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - quickly, in one place.